The cluster is dominated by passive/index managers and likely reflects index rebalancing or broad sector rotation into small-cap biotech, not a company-specific catalyst. With Wellington's massive DOUBLED position (+1792% to $29.8M) as the sole active manager signal, watch for next earnings and pipeline updates to see if conviction follows.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $13.46entry
- T+1 · 5mo ago +5.57%α +5.03% · $14.21
- T+5 · 5mo ago +21.62%α +21.19% · $16.37
- T+20 · 4mo ago +36.70%α +34.81% · $18.40
- T+60 · 2mo ago +28.23%α +23.84% · $17.26
How similar events traded
Executive Summary
A strong institutional cluster for Trevi Therapeutics (TRVI) in Q3 2025 shows 8 buyers adding $111.4M in aggregate holdings vs. 5 sellers trimming $5.4M, a heavily lopsided net accumulation. The buying is dominated by passive/index funds (Fidelity, Morgan Stanley, Schwab, Wells Fargo, Invesco, BofA) and two asset managers (Wellington, Legal & General), while the selling comes from quant and asset managers (Citadel, RenTech, Point72, Dimensional, Barclays). The magnitude of net buying ($111.4M) relative to a $1.9B market cap is notable (~5.9% of cap), but the active vs. passive split and lack of disclosed catalysts suggest the move was driven primarily by index-related flows and passive rebalancing into a rising biotech stock, not a concentrated active thesis.
Key Financial Metrics
Institutional Positions
Net institutional flow: $106.0M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Fidelity | DOUBLED | +795.4% | $30.2M | $28.2M |
| Morgan Stanley | DOUBLED | +320.1% | $39.4M | $33.8M |
| Wellington Management Group | DOUBLED | +1792% | $29.8M | $28.8M |
| BofA | ADD | +67.4% | $16.8M | $10.8M |
| Schwab | DOUBLED | +256.9% | $7.4M | $6.1M |
▼ Sellers (5)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | NEAR_EXIT | -92.2% | $7.2M | -$6.3M |
| Point72 | TRIM | -45.5% | $9.5M | -$837.2K |
| RenTech | TRIM | -40.1% | $2.7M | $7.0K |
| Dimensional Fund Advisors | TRIM | -67.3% | $695.0K | -$315.8K |
| Barclays | TRIM | -57.9% | $3.0K | $2.0M |
Key Facts
- 8 institutions accumulated $129.2M in aggregate TRVI holdings, adding $111.4M in net new value during Q3 2025
- 5 institutions reduced holdings by $5.4M, with Citadel (NEAR_EXIT, -92.2%) leading the sell-side
- 6 of 8 buyers are mega-passive/index-tracking managers (Fidelity, Morgan Stanley, Schwab, Invesco, BofA, Wells Fargo), the signal is dominated by passive rebalancing
- Two active asset managers, Wellington (DOUBLED, +1792% to $29.8M) and Legal & General (DOUBLED, +870% to $750K), also added meaningfully
- The cluster data is from 2025-Q3 (ended Sep 30) and subject to the 45-day 13F filing lag, current positions may differ
Financial Impact
8 buyers added $111.4M in new net value (total holdings $129.2M) while 5 sellers reduced by $5.4M, net institutional accumulation of ~$106M in Q3 2025
Risk Factors
- 13F data is retrospective (quarter-end Sep 30, filed by Nov 14); passive inflows may have already been unwound or reversed in Q4
- The sell-side includes Citadel and Point72, quant selling may indicate alpha decay or hedging that counters the passive buying thesis
- No specific catalyst (pipeline milestone, approval, partnership) is evident from the cluster data alone to justify forward price appreciation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-TRVI-2025-Q3 |
Track record
12 reports on TRVI
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Viewing Entry $13.46 to $18.40 ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers